Eli Lilly abandons its plans to pitch its blockbuster contender mirikizumab for psoriasis after sizing up heavyweight rivals
Last July, Eli Lilly execs had nothing but good things to say about the “promising” late-stage psoriasis data they had gathered together on their IL23 drug mirikizumab. The drug had hit the primary and all key secondary endpoints, and they were getting ready to roll it out to the FDA and regulatory agencies around the world.
“We look forward to bringing mirikizumab to market to provide patients with an additional treatment option that has the potential to provide near complete or complete skin clearance as measured by PASI 90 and PASI 100, with sustained results at 52 weeks,” Lilly USA president Patrik Jonsson noted at the time, as the company beamed over its head-to-head win over Cosentyx, the rival drug everyone developing new therapies likes to test against.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.